Literature DB >> 11407909

Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.

C H Miao1, A R Thompson, K Loeb, X Ye.   

Abstract

Naked DNA transfer of a high-expressing human factor IX (hFIX) plasmid yielded long-term (over 1 1/2 years) and therapeutic-level (0.5-2 microg/ml) gene expression of hFIX from mouse livers. The expression cassette contained a hepatic locus control region from the ApoE gene locus, an alpha1-anti-trypsin promoter, hFIX cDNA, a portion of the hFIX first intron, and a bovine growth hormone polyadenylation signal. In contrast, a hFIX plasmid containing the expression cassette without effective regulatory elements produced initially low-level gene expression that rapidly declined to undetectable levels. Southern analyses of the cellular DNA indicated that the majority of the input genome from either vector persisted as episomal forms of the original plasmids. Together with RT-PCR analyses of the transcripts, these data indicated that at least two processes are critical for sustained gene expression: persistence of vector DNA and transcriptional/posttranscriptional activation. Liver regeneration after partial hepatectomy resulted in a significant decline in transgene expression, further suggestive of decreased episomal plasmid maintenance rather than transgene integration. Transaminase levels and liver histology showed that rapid intravenous plasmid injection into mice induced transient focal acute liver damage (< 5% of hepatocytes), which was rapidly repaired within 3 to 10 days and resulted thereafter in histologically normal tissue. No significant differences were observed between rapid injection of plasmid and saline control solutions. Transient, very low level antibodies directed against hFIX did not prevent the circulation of therapeutic levels of the protein. Gene transfer of hFIX plasmid DNA into liver elicited neither transgene-specific cytotoxic effect nor long-term toxicity. These results demonstrate that long-term expression of hFIX can be achieved by nonviral plasmid transfer and suggest that this occurs independent of integration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407909     DOI: 10.1006/mthe.2001.0333

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  36 in total

1.  Intracellular gene transfer in rats by tail vein injection of plasmid DNA.

Authors:  Tian Zhou; Kenya Kamimura; Guisheng Zhang; Dexi Liu
Journal:  AAPS J       Date:  2010-09-22       Impact factor: 4.009

2.  Efficient microbubble- and ultrasound-mediated plasmid DNA delivery into a specific rat liver lobe via a targeted injection and acoustic exposure using a novel ultrasound system.

Authors:  Shuxian Song; Misty Noble; Samuel Sun; Liping Chen; Andrew A Brayman; Carol H Miao
Journal:  Mol Pharm       Date:  2012-07-25       Impact factor: 4.939

3.  Tissue-specific characteristics of in vivo electric gene: transfer by tissue and intravenous injection of plasmid DNA.

Authors:  Oranuch Thanaketpaisarn; Makiya Nishikawa; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 4.  Nonviral gene delivery: what we know and what is next.

Authors:  Xiang Gao; Keun-Sik Kim; Dexi Liu
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

5.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.

Authors:  Ru Zhang; Qiang Wang; Lin Zhang; Saijuan Chen
Journal:  Front Med       Date:  2015-02-07       Impact factor: 4.592

6.  Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery.

Authors:  Z P Shen; A A Brayman; L Chen; C H Miao
Journal:  Gene Ther       Date:  2008-04-03       Impact factor: 5.250

7.  Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.

Authors:  Wei Lu; Qingzhang Zhou; Hao Yang; Hao Wang; Yexing Gu; Qi Shen; Jinglun Xue; Xiaoyan Dong; Jinzhong Chen
Journal:  Front Med       Date:  2016-04-06       Impact factor: 4.592

8.  Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

Authors:  Carol H Miao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-23

9.  Transient expression of proteins by hydrodynamic gene delivery in mice.

Authors:  Daniella Kovacsics; Jayne Raper
Journal:  J Vis Exp       Date:  2014-05-05       Impact factor: 1.355

10.  CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

Authors:  Carol H Miao; Benjamin R Harmeling; Steven F Ziegler; Benjamin C Yen; Troy Torgerson; Liping Chen; Roger J Yau; Baowei Peng; Arthur R Thompson; Hans D Ochs; David J Rawlings
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.